Abstract:Antibody-drug conjugates (ADCs) are a heterogeneous mixture of conjugated species with varied drug loadings. Depending on conjugation sites, linkers and drugs can exhibit different stability as influenced by the solvent-accessibility and local charge, resulting in different ADC efficacy, pharmacokinetics, and toxicity. Conjugation site analysis is critical for ADC structural characterization to assure product quality and consistency. It enables early conjugation studies at site-specific levels, confirms the absence of unexpected products to support conjugation process development, and aids in ensuring lot-to-lot consistency for comparability studies. Peptide mapping using liquid chromatography-tandem mass spectrometry is the industry standard method for analyzing conjugation sites. However, some concerns remain for this approach as the large and hydrophobic drug moieties often result in poor MS/MS fragmentation quality and impede the identification of conjugation sites. Additionally, the ionization discrepancy between conjugated and unconjugated peptides can lead to a relatively large bias for site occupancy calculation. In this work, we present a simple drug deconjugation-assisted peptide mapping method to identify and quantify the drug conjugation for ADCs with protease-cleavable linkers. Papain-based drug deconjugation was used to remove the highly hydrophobic drug moiety, which significantly improved the quantitation accuracy of conjugation level and the fragmentation quality. Sample preparation conditions were optimized to avoid introducing artificial modifications, allowing the tracking of initial sample status and subsequent changes of quality attributes during process development and stability assessment. This method was applied to analyze thermally-stressed ADC samples to monitor changes of site-specific conjugation levels, DAR, succinimide hydrolysis of the linker, and various PTMs. We believe this is an effective and straightforward tool for conjugation site analysis while simultaneously monitoring multiple quality attributes for ADCs with protease-cleavable linkers.

[Bioanalysis in the development of antibody-drug conjugates]

Bioanalytical assays for pharmacokinetic and biodistribution study of Antibody-Drug Conjugates

In situ quantitative bioanalysis of monomethyl auristatin E-conjugated antibody-drug conjugates by flow cytometry.

Bibliometric analysis of antibody-drug conjugates

Enhanced Pharmacokinetic Bioanalysis of Antibody–drug Conjugates using Hybrid Immunoaffinity Capture and Microflow LC-MS/MS

Development of antibody-drug conjugates in cancer: Overview and prospects

Clinical pharmacology strategies in supporting drug development and approval of antibody–drug conjugates in oncology

Development of antibody used by antibody-drug conjugates

Antibody–drug conjugates in cancer therapy: mechanisms and clinical studies

Detection of antibody-conjugate payload in cynomolgus monkey serum by a high throughput capture LC-MS/MS bioanalysis method

A new anti-human Fc method to capture and analyze ADCs for characterization of drug distribution and the drug-to-antibody ratio in serum from pre-clinical species

ADCdb: the Database of Antibody-Drug Conjugates

Drug Deconjugation-assisted Peptide Mapping by LC-MS/MS to Identify Conjugation Sites and Quantify Site Occupancy for Antibody-drug Conjugates

Meta‐Analysis of Exposure‐Adverse Event Relationships for Antibody–Drug Conjugates

Site-Specific Stability Evaluation of Antibody-Drug Conjugate in Serum Using a Validated Liquid Chromatography-Mass Spectrometry Method

ADME and DMPK considerations for the discovery and development of antibody drug conjugates (ADCs)

Antibody Drug Conjugates: Design and Selection of Linker, Payload and Conjugation Chemistry

Digestion-Free Middle-down Mass Spectrometry Method for Absolute Quantification of Conjugated Payload from ADCs

Conjugation site characterization of antibody-drug conjugates using electron-transfer/higher-energy collision dissociation (EThcD)

Antibody-drug conjugates: recent advances in conjugation and linker chemistries

Antibody-Drug Conjugates: Design, Formulation and Physicochemical Stability